In addition, another TIGIT-targeting antibody, Tiragolumab, in combination with Tecentriq (anti-PDL-1 mAb), has received a breakthrough therapy designation by the US FDA for the treatment of non-small cell lung carcinoma (NSCLC) that express high PDL-1 [64]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.